Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases.

Abstract

Rapid-response vaccine production platform technologies, including RNA vaccines, are being developed to combat viral epidemics and pandemics. A key enabler of rapid response is having quality-oriented disease-agnostic manufacturing protocols ready ahead of outbreaks. We are the first to apply the Quality by Design (QbD) framework to enhance rapid-response RNA vaccine manufacturing against known and future viral pathogens. This QbD framework aims to support the development and consistent production of safe and efficacious RNA vaccines, integrating a novel qualitative methodology and a quantitative bioprocess model. The qualitative methodology identifies and assesses the direction, magnitude and shape of the impact of critical process parameters (CPPs) on critical quality attributes (CQAs). The mechanistic bioprocess model quantifies and maps the effect of four CPPs on the CQA of effective yield of RNA drug substance. Consequently, the first design space of an RNA vaccine synthesis bioreactor is obtained. The cost-yield optimization together with the probabilistic design space contribute towards automation of rapid-response, high-quality RNA vaccine production.

• Authors: Damien van de Berg, Zoltán Kis, Carl Fredrik Behmer, Karnyart Samnuan, Anna K Blakney, Cleo Kontoravdi, Robin Shattock, Nilay Shah
• Journal: NPJ vaccines (NPJ Vaccines) Vol. 6 Issue 1 Pg. 65 (Apr 29 2021) ISSN: 2059-0105 [Electronic] England
• PMID: 33927197 (Publication Type: Journal Article)